Search Results

You are looking at 51 - 60 of 258 items for :

  • "oxaliplatin" x
  • Refine by Access: All x
Clear All
Full access

Oxaliplatin as Induction Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma Principal Investigator: Sarbajit Mukherjee, MD, MS Condition: Esophageal or gastroesophageal junction adenocarcinoma Institutions: Roswell Park

Full access

Oxaliplatin as Induction Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma Principal Investigator: Sarbajit Mukherjee, MD, MS Condition: Esophageal or gastroesophageal junction adenocarcinoma Institutions: Roswell Park

Full access

Oxaliplatin as Induction Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma Principal Investigator: Sarbajit Mukherjee, MD, MS Condition: Esophageal or gastroesophageal junction adenocarcinoma Institutions: Roswell Park

Full access

by the ORP. This feature highlights an NCCN study funded through the grant mechanism. Use of Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma Principal Investigator

Full access

by the ORP. This feature highlights an NCCN study funded through the grant mechanism. Use of Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma Principal Investigator

Full access

Jean L. Grem

C-10 evaluated bolus and infusional 5-FU, leucovorin, and oxaliplatin (FOLFOX6) plus bevacizumab for patients with unresectable stage IV colon cancer and a synchronous asymptomatic primary tumor. 11 The results indicated that patients with

Full access

Crystal S. Denlinger and Andrea M. Barsevick

Edited by Kerrin G. Robinson

Fleming T Macdonald J . Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma . N Engl J Med 1990 ; 322 : 352 – 358 . 7 de Gramont A Boni C Navarro M . Oxaliplatin/5FU/LV in adjuvant colon cancer: updated efficacy

Full access

Mary F. Mulcahy and Al B. Benson III

phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines . Ann Oncol 1996 ; 7 : 95 – 98 . 11 Levi F Perpoint B Garufi C

Full access

-roshevsky@northwestern.edu ClinicalTrials.gov Identifier: NCT01008917 Pralatrexate in Combination with Oxaliplatin in Advanced Esophagogastric Cancer: A Phase II Trial With Predictive Molecular Correlates Principal Investigator: Nikhil I. Khushalani, MD Condition

Full access

Wells A. Messersmith

treatment with the best chance of success. Adjuvant Therapy Although 11 agents have been approved by the FDA for CRC, only 3 are used in the adjuvant setting (fluorouracil [5-FU], capecitabine, and oxaliplatin) and only 2 (cetuximab and panitumumab